DeCure's autonomous Immuno AI scientist is researching a drug-repurposing hypothesis for Myasthenia gravis — screening already-approved drugs against its 38-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMyasthenia gravis maps to a 38-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for myasthenia gravis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
Fc gamma receptor and transporter (FCGRT) — FCGRT is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet cysdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6C98 · 1.85 Å · ligand CYSTEINE (CYS). Experimental structure, not a prediction.
What the evidence adds up to
Myasthenia gravis in Greece, based on a population study of 843 seropositive patients from 1983 to 1997, had an average annual incidence of 7.40 per million population between 1992 and 1997, with a point prevalence of 70.63 per million on 1 July 1997. The average age at onset was 46.50 years, and the overall annual mortality rate was 0.67 per million, with 0.43 per million attributed directly to myasthenia gravis. The women-to-men incidence ratio was 1:1.04, but the prevalence ratio was 1.41:1, a difference the authors predicted would increase if patients with onset before 1983 were included.
Management of myasthenia gravis follows a graded approach, starting with cholinesterase inhibitors for mild symptoms and advancing to immunomodulating medications for more severe weakness. A 2004 review described the illness as once severe and often fatal but now manageable with several relatively safe and effective therapies, with drug selection based on time to clinical effect and adverse effects. A 2018 review stated that appropriate use of established options, including cholinesterase inhibitors and a broad spectrum of immunosuppressive, immunomodulating, or cell-depleting agents, allows the great majority of patients to lead a normal life, and it recommended specialised centres integrating outpatient and inpatient resources.
Current immunotherapy, as described in a 2009 review, is directed at generalised modulation and suppression of the immune system, which is effective in many patients but carries significant adverse effects from global immune suppression. That review noted future directions toward focused immunotherapies aiming to improve outcomes while lessening side effects. A 2023 review stated that treatment has been extensively developed in recent decades but that a standardised standard still needs to be used, and that treatment strategy is associated with patient prognosis, economic costs, and complications.
What remains missing is a standardised treatment standard that accounts for patient prognosis, economic costs, and complications, as well as prospective trials of targeted immunotherapies that can demonstrate reduced side-effect burdens compared with current broad immunosuppression. The epidemiological data come from a single country and a period ending in 1997, so contemporary incidence and prevalence figures for other populations are not provided.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Neurology Neurosurgery & Psychiatry · 2001 · 105 citations · open access
Epidemiology of seropositive myasthenia gravis in Greece
AbstractOBJECTIVES: To study the epidemiological characteristics of myasthenia gravis in Greece. METHODS: A population based study was carried out of seropositive myasthenia gravis in Greece for the period from 1 January 1983 to 30 June 1997; 843 patients were studied. RESULTS: The average annual incidence for the period 1992-7, for which the database is complete, was 7.40/million population/year (women 7.14; men 7.66). On 1 July 1997, there were 740 prevalent cases. The point prevalence rate was 70.63/million (women 81.58; men 59.39). The average overall annual mortality rate in the patients was 0.67/million population (women 0.53; men 0.82), and the mortality rate attributed to myasthenia gravis was 0.43/million population (women 0.41; men 0.45). The average age at onset was 46.50 years (women 40.16; men 54.46), and the mean age of the prevalent patients was 52.58 (women 47.65; men 59.48). The women:men incidence ratio was 1:1.04, and the prevalence ratio was 1.41:1. It is predicted that the prevalence and women: men prevalence ratio would increase if the patient list included all patients with a date of onset before 1983. CONCLUSIONS: The largest epidemiological study ever performed on myasthenia gravis is presented. The most important epidemiological indexes are provided.
AbstractAlthough once a severe and often fatal illness, myasthenia gravis can now be well managed with several relatively safe and effective therapies. Management involves a graded approach, beginning with cholinesterase inhibitors for mild symptoms and advancing to immunomodulating medications for more severe weakness. There are several immunomodulating agents from which to choose; selection is based largely on time to clinical effect and adverse effects. This review will discuss the selection and use of therapies for patients with myasthenia gravis.
Neurology International Open · 2018 · 12 citations · open access
Treatment Standards and Individualized Therapy of Myasthenia Gravis
AbstractAbstract A wide range of established treatment options is currently available for myasthenia gravis. These include cholinesterase inhibitors for symptomatic treatment and a broad spectrum of immunosuppressive, immunomodulating or cell-depleting options to modify the underlying immunological process. Appropriate use allows the great majority of patients to lead a normal life. Specialized centers integrating outpatient and in-hospital resources as well as interdisciplinary competences offer important advantages for optimum individualized therapy.
Current and Future Immunotherapy in Myasthenia Gravis
AbstractCurrent therapy for myasthenia gravis is directed towards generalized modulation and suppression of the immune system. These approaches have been extensively studied and are effective in many patients with myasthenia, but at the cost of significant adverse effects due to the global effects on the immune system. Future directions in therapy are geared towards focused immunotherapies that aim to improve outcomes while lessening the burden of side effects. This paper reviews both the current accepted treatments for myasthenia gravis as well as promising targeted therapies in development.
Journal of Biosciences and Medicines · 2023 · 0 citations · open access
New Progress in the Treatment of Myasthenia Gravis
AbstractIn recent decades, the treatment of myasthenia gravis has been extensively developed, but a standardized standard still needs to be used. Its treatment strategy is associated with patient prognosis, economic costs, and complications. This article reviews the pathogenesis, treatment methods, and complications of myasthenia gravis, providing new ideas for diagnosing and treating myasthenia gravis and fully embodies the principle of safety and precision.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
